From August 2017 through July 2018, the FDA approved 14 new anticancer therapeutics. These included nine molecularly targeted therapeutics, part of the new wave of precision medicines, as well as two targeted forms of radiotherapy and two new CAR T-cell therapies.
There are preclinical studies of vaccines that target oncogenes (early genetic changes that initiate cancers). We expect to see these tested in the next few years in individuals who are at high risk for cancer development.
Source: AARP magazine October -November 2018 Elizabeth M, Jaffee oncologist and President of the American Association for Cancer Research.
IF YOU LIKE THESE POSTS, PLEASE CONSIDER CLICKING THE DONATION BUTTON ABOVE. THANK YOU!